Skip to contentB
BioMarin Pharmaceutical Inc
B
BMRNBioMarin Pharmaceutical Inc Q2 2024 · 10-Q
Revenue$712.03M$712.03M+19.6% vs Q2 2023 Net Income$107.17M$107.17M+91.2% vs Q2 2023 EPS Diluted$0.55$0.55+89.7% vs Q2 2023 Operating Income$120,452,000+83.7% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioMarin Pharmaceutical Inc · CIK 1048477 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$97,435,000+101.0% Margins · derivedOperating margin16.9%+5.9 pt vs Q2 2023
Net margin15.1%+5.6 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 5, 2024 · 36 d after period end